Claritas Pharmaceuticals, Inc.

OTCPK:CLAZ.F Stock Report

Market Cap: US$37.0

Claritas Pharmaceuticals Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Bob Farrell

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure8.5yrs
CEO ownershipn/a
Management average tenure8yrs
Board average tenure6.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bob Farrell's remuneration changed compared to Claritas Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2021n/an/a

US$2m

Jun 30 2021n/an/a

US$2m

Mar 31 2021n/an/a

-US$12m

Dec 31 2020US$300kUS$300k

US$4m

Sep 30 2020n/an/a

-US$7m

Jun 30 2020n/an/a

-US$8m

Mar 31 2020n/an/a

-US$875k

Dec 31 2019US$300kUS$300k

-US$21m

Sep 30 2019n/an/a

-US$12m

Jun 30 2019n/an/a

-US$9m

Mar 31 2019n/an/a

US$2m

Dec 31 2018US$300kUS$300k

US$7m

Compensation vs Market: Insufficient data to establish whether Bob's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Bob's compensation with company performance.

CEO

Bob Farrell

8.5yrs

Tenure

US$300,000

Compensation

Mr. Robert Farrell, also known as Bob, J.D., serves as the President of Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) and has been its Chief Executive Officer since October 10, 2017...

Leadership Team

NamePositionTenureCompensationOwnership
Robert Farrell
Chairman8.5yrsUS$300.00kno data
Victoria Rudman
Interim CFO9.8yrsUS$75.00kno data
Seth Yakatan
Co-Founderno dataUS$22.50kno data
Stuart Silverman
Chair of Scientific Advisory Board and Vice President of Medical Affairsno datano datano data
Sari Prutchi-Sagiv
Chief Scientific Officer7.6yrsUS$212.00kno data
Moshe Yeshurun
Chief Medical Officer7.6yrsUS$162.00kno data
Amos Rosenthal
Head of Chemistryno datano datano data

8.0yrs

Average Tenure

56yo

Average Age

Experienced Management: CLAZ.F's management team is seasoned and experienced (8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robert Farrell
Chairman8.1yrsUS$300.00kno data
Stuart Silverman
Chair of Scientific Advisory Board and Vice President of Medical Affairs9.3yrsno datano data
Robert S. Langer
Member of Scientific Advisory Board8.6yrsno datano data
Joseph Tam
Member of Scientific Advisory Boardno datano datano data
Yanekl Gabet
Member of Scientific Advisory Boardno datano datano data
Deborah Kado
Member of Scientific Advisory Boardno datano datano data
Yong-Hui Jiang
Member of Scientific Advisory Boardno datano datano data
Joseph Lynch
Member of Strategic & Scientific Advisory Board6.7yrsno datano data
Li Zhang
Member of Strategic & Scientific Advisory Board6.7yrsno datano data
Hanns Zeilhofer
Member of Strategic & Scientific Advisory Board6.7yrsno datano data
Salvatore Cuzzocrea
Independent Director3.8yrsno datano data
Perenlei Enkhbaatar
Independent Director3.8yrsno datano data

6.7yrs

Average Tenure

Experienced Board: CLAZ.F's board of directors are considered experienced (6.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/20 13:28
End of Day Share Price 2025/01/02 00:00
Earnings2021/09/30
Annual Earnings2020/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Claritas Pharmaceuticals, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas LoeEchelon Wealth Partners Inc.